Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7936)
All Articles published online
|
Publishing Process of This Article
|
May 28, 2015 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jin Y, Lin Y, Lin LJ, Zheng CQ. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World J Gastroenterol 2015; 21(20): 6352-6360 [PMID: 26034371 DOI: 10.3748/wjg.v21.i20.6352] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i20/6352.htm |
| Number | Citing Articles |
| 1 |
Paweł Moćko, Paweł Kawalec, Andrzej Pilc. Safety Profile of Biologic Drugs in the Treatment of Inflammatory Bowel Diseases: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. Clinical Drug Investigation 2017; 37(1): 25 doi: 10.1007/s40261-016-0459-y
|
| 2 |
J.K. Yamamoto-Furusho, F. Bosques-Padilla, P. Daffra, J.A. De Paula, J. Etchevers, M.T. Galiano, P. Ibañez, F. Juliao, P.G. Kotze, J.M. Marroquín de la Garza, R. Monreal Robles, J.L. Rocha, F. Steinwurz, R. Vázquez-Frías, G. Veitia, C. Zaltman. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Revista de Gastroenterología de México (English Edition) 2017; 82(2): 134 doi: 10.1016/j.rgmxen.2016.07.004
|
| 3 |
Dong Yeon Jeong, Seung Kim, Min Ji Son, Chei Yun Son, Jong Yeob Kim, Andreas Kronbichler, Keum Hwa Lee, Jae Il Shin. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmunity Reviews 2019; 18(5): 439 doi: 10.1016/j.autrev.2019.03.002
|
| 4 |
J.K. Yamamoto-Furusho, F. Bosques-Padilla, P. Daffra, J.A. De Paula, J. Etchevers, M.T. Galiano, P. Ibañez, F. Juliao, P.G. Kotze, J.M. Marroquín de la Garza, R. Monreal Robles, J.L. Rocha, F. Steinwurz, R. Vázquez-Frías, G. Veitia, C. Zaltman. Situaciones especiales en la enfermedad inflamatoria intestinal: primer consenso latinoamericano de la Pan American Crohn's and Colitis Organisation (PANCCO) (Segunda parte). Revista de Gastroenterología de México 2017; 82(2): 134 doi: 10.1016/j.rgmx.2016.07.005
|
| 5 |
Elisa K. Boden, Donna M. Shows, Michael V. Chiorean, James D. Lord. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease. Digestive Diseases and Sciences 2018; 63(9): 2419 doi: 10.1007/s10620-018-4924-8
|
| 6 |
E. B. Kornilova, K. I. Polyakova, T. V. Shkurko, O. V. Knyazev, A. D. Ermolaeva, M. V. Davydovskaya, T. N. Ermolaeva, A. G. Fisun. Economic rationale for administration of vedolizumab in patients with inflammatory bowel disease in Moscow. Dokazatel'naya gastroenterologiya 2019; 8(3): 55 doi: 10.17116/dokgastro2019803155
|
| 7 |
Andreas Stallmach, Carsten Schmidt, Niels Teich. Vedolizumab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2016; 10(2): 165 doi: 10.1586/17474124.2016.1123618
|
| 8 |
Katerina Pantavou, Anneza I Yiallourou, Daniele Piovani, Despo Evripidou, Silvio Danese, Laurent Peyrin-Biroulet, Stefanos Bonovas, Georgios K Nikolopoulos. Efficacy and safety of biologic agents and tofacitinib in moderate‐to‐severe ulcerative colitis: A systematic overview of meta‐analyses. United European Gastroenterology Journal 2019; 7(10): 1285 doi: 10.1177/2050640619883566
|
| 9 |
Beatriz Sicilia, Santiago García-López, Yago González-Lama, Yamile Zabana, Joaquín Hinojosa, Fernando Gomollón. Guía GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodología GRADE. Gastroenterología y Hepatología 2020; 43: 1 doi: 10.1016/j.gastrohep.2020.07.001
|
| 10 |
Claudia Fuxman, Beatriz Sicilia, María Eugenia Linares, Santiago García-López, Ramiro González Sueyro, Yago González-Lamac, Yamile Zabana, Joaquín Hinojosa, Manuel Barreiro-de Acosta, Domingo Balderramo, Deborah Balfour, Maricel Bellicoso, Pamela Daffra, Daniela Morelli, Marina Orsi, Astrid Rausch, Orlando Ruffinengo, Martín Toro, Alicia Sambuelli, Abel Novillo, Fernando Gomollón, Juan Andrés De Paula. Guía GADECCU 2022 para el tratamiento de la colitis ulcerosa. Adaptación y actualización de la Guía GETECCU 2020. Gastroenterología y Hepatología 2023; 46: S1 doi: 10.1016/j.gastrohep.2023.01.009
|
| 11 |
Xinyang Li, Jun Shen, Zhihua Ran. Crosstalk between the gut and the liver via susceptibility loci: Novel advances in inflammatory bowel disease and autoimmune liver disease. Clinical Immunology 2017; 175: 115 doi: 10.1016/j.clim.2016.10.006
|
| 12 |
Antonio Tursi, Mariabeatrice Principi, Marcello Picchio, Floriana Giorgio, Cosimo Damiano Inchingolo, Domenico Piscitelli, Enzo Ierardi. Persistence of endoscopic rectal inflammation in UC treated with infliximab is not linked to ineffective TNFα downregulation. Gut 2016; 65(3): 539 doi: 10.1136/gutjnl-2015-310284
|
| 13 |
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu’Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger, Kevin J Barrett, R Justin Davies, Cathy Bennett, Stuart Gittens, Malcolm G Dunlop, Omar Faiz, Aileen Fraser, Vikki Garrick, Paul D Johnston, Miles Parkes, Jeremy Sanderson, Helen Terry, Daniel R Gaya, Tariq H Iqbal, Stuart A Taylor, Melissa Smith, Matthew Brookes, Richard Hansen, A Barney Hawthorne. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68(Suppl 3): s1 doi: 10.1136/gutjnl-2019-318484
|
| 14 |
Prasanta Debnath, Pravin M. Rathi. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflammatory Intestinal Diseases 2021; 6(1): 1 doi: 10.1159/000512805
|
| 15 |
Elizabeth C. Goode, Simon M. Rushbrook. A review of the medical treatment of primary sclerosing cholangitis in the 21st century. Therapeutic Advances in Chronic Disease 2016; 7(1): 68 doi: 10.1177/2040622315605821
|